Global Next Generation Diabetes Therapy and Drug Delivery Market Analysis from 2022 to 2034 Containing Market Size, Share along with its CAGR, Forecast and Trends
Top Countries — Revenue
USD Million/Billion
Loading…
Share Distribution
Loading…
Market Dynamics of Global Next Generation Diabetes Therapy and Drug Delivery Market Analysis
↑ Growth Drivers
Growing diabetes epidemic will lead to boost Next Generation Diabetes Therapy and Drug Delivery Market growth
Technological advancements in drug delivery
Growing adoption of non-invasive therapies
↓ Restraints
Regulatory & Approval Processes and cost of innovation may hamper the growth of Next Generation Diabetes Therapy and Drug Delivery Market
High price of advanced treatments
Challenges in developing and manufacturing sophisticated medication delivery systems
~ Trends
Rise of wearable and connected devices
Development of smart insulin
Access the full forecast model.
Country-level data · Company profiles · Editable dataset · Analyst consultation included.
Global Next Generation Diabetes Therapy and Drug Delivery Market Analysis — Presence
Interactive World Map
Click countries to explore
Loading map…
Regional and Country Analysis
North America — United States, Canada, Mexico
Europe — United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Switzerland, Luxembourg, Rest of Europe
Asia Pacific — China, Japan, South Korea, India, Australia, Singapore, Taiwan, South East Asia, Rest of APAC
South America — Brazil, Argentina, Colombia, Peru, Chile, Rest of South America
Middle East — Saudi Arabia, Turkey, UAE, Egypt, Qatar, Rest of Middle East
Africa — East Africa, West Africa, North Africa, South Africa
Region / Country
2021 (A)
2025 (A)
2033 (P)
CAGR
A = Actual · E = Estimated · P = Projected · 🔒 Locked values require full access. Click headers to sort.
Charts are illustrative — exact values, country-level breakdowns, and full forecast in the paid report. Request a Free Sample PDF.
To learn more about market share and segmentation, request the free sample pages.
Competitive Landscape of the Global Next Generation Diabetes Therapy and Drug Delivery Market Analysis
In no particular order of rank
Competitive Landscape of the Next Generation Diabetes Therapy and Drug Delivery Market
The market for next-generation diabetes therapy and drug delivery is highly competitive, with major competitors such as Abbott Laboratories, Novo Nordisk, Dexcom, and Medtronic vying for market share. These businesses are committed to innovation, creating cutting-edge products like continuous glucose monitors and intelligent insulin delivery systems. In this quickly changing industry, companies often look to grow their portfolios and solidify their market positions through strategic alliances, mergers, and acquisitions.
In February 2025, Gan & Lee Pharmaceuticals (hereafter referred to as "Gan & Lee," stock code: 603087.SH) announced that the first participant has been successfully dosed in a large-scale Phase 3 clinical trial (OPTIMUM-2) of Bofanglutide (research code: GZR18), a bi-weekly glucagon-like peptide-1 receptor agonist (GLP-1RA) independently developed by Gan & Leem, in Chinese participant with type 2 diabetes mellitus (T2DM).
https://www.ganlee.com/detail/769.html
In December 2024, NuGen Medical Devices launched its InsuJet needle-free insulin delivery device in Canada, securing orders for 2,500 units and 750 starter kits, generating $670,000 in revenue, and approved for use in 42 countries, using a spring-loaded mechanism for fast, painless insulin delivery.
https://www.drugdeliverybusiness.com/nugen-launches-needle-free-insulin-delivery-device-canada/
In September 2024, Senseonics Holdings, Inc. and Ascensia Diabetes Care announced that the U.S. Food and Drug Administration (FDA) has approved the next-generation Eversense 365 CGM system for individuals aged 18 and older with Type 1 and Type 2 diabetes. Eversense 365 is the world’s first CGM system with a one-year sensor, marking a major advancement in diabetes technology and management. Unlike short-term CGM systems that require sensor changes every 10-14 days, Eversense 365 offers a single insertion and "Day 1" each year, reducing the frequency of sensor replacements. Its 12-month sensor lifespan minimizes the disruptions caused by frequent sensor failures or changes in traditional systems.
https://www.senseonics.com/investor-relations/news-releases/2024/09-17-2024-120118174
In August 2024, Eli Lilly announced positive topline results from the three-year SURMOUNT-1 study (176-week treatment period), assessing the efficacy and safety of once-weekly tirzepatide (Zepbound and Mounjaro) for long-term weight management and delaying the progression to diabetes in adults with pre-diabetes and obesity or overweight. The weekly injections of tirzepatide (5 mg, 10 mg, 15 mg) reduced the risk of progression to type 2 diabetes by 94% in adults with pre-diabetes and obesity or overweight compared to placebo.
https://investor.lilly.com/news-releases/news-release-details/tirzepatide-reduced-risk-developing-type-2-diabetes-94-adults
In May 2024, Eli Lilly, headquartered in Indianapolis, announced plans to invest an additional USD 5.3 billion in the construction of a large manufacturing facility in Lebanon, Indiana, located 30 miles away. This investment will enhance the production capacity of active pharmaceutical ingredients (APIs) for its injectable tirzepatide products, Mounjaro for type 2 diabetes and Zepbound for obesity.
https://www.fiercepharma.com/manufacturing/eli-lilly-invests-additional-53b-production-diabetes-obesity-drugs-indiana
May 2021: The medical technology company Medtronic plc has been awarded the CE (Conformité Européenne) Mark for its Guardian 4 sensor3. This sensor eliminates the need for fingersticks while calibrating or making treatment decisions for diabetes. Due to the CE Mark, this next-generation sensor can be linked with Medtronic or the MiniMed 780G insulin pump system. (Source:https://news.medtronic.com/2021-05-26-Medtronic-Secures-Two-CE-Mark-Approvals-for-Guardian-4-Sensor-for-InPen-MDI-Smart-Insulin-Pen) September 2020: DexCom, Inc., the leading provider of real-time continuous glucose monitoring (rtCGM) for people with diabetes, announced the creation of the first registry in history dedicated to monitoring the results of CGM use in hospitals during the COVID-19 pandemic by patients and healthcare professionals. (Source:https://investors.dexcom.com/news/news-details/2020/Dexcom-Announces-First-Ever-Registry-Dedicated-to-Tracking-Outcomes-of-In-Hospital-Real-Time-CGM-Use-in-Response-to-the-COVID-19-Pandemic/default.aspx) April 2020: Dexcom announced that the company is temporarily making its Dexcom G6 CGM System available for remote patient monitoring in the hospital setting due to the COVID-19 public health crisis, the need to maintain personal protective equipment, and the desire to decrease the frequency of hospital staff exposure to the coronavirus. (Source:https://www.dexcom.com/news/dexcom-cgm-hospital-covid19)
Click any bar or cell to request the full company profile
Company
2022 (A)
2023 (A)
2024 (A)
2025 (A)
Johnson & Johnson
•••
•••
•••
•••
•••
•••
•••
•••
Abbott Laboratories
•••
•••
•••
•••
•••
•••
•••
•••
Medtronic
•••
•••
•••
•••
•••
•••
•••
•••
Sanofi
•••
•••
•••
•••
•••
•••
•••
•••
Novo Nordisk
•••
•••
•••
•••
•••
•••
•••
•••
MannKind Corporation
•••
•••
•••
•••
•••
•••
•••
•••
Enteris BioPharma
•••
•••
•••
•••
•••
•••
•••
•••
Dexcom
•••
•••
•••
•••
•••
•••
•••
•••
Senseonics
•••
•••
•••
•••
•••
•••
•••
•••
Medtech
•••
•••
•••
•••
•••
•••
•••
•••
Synertech
•••
•••
•••
•••
•••
•••
•••
•••
Relmada Therapeutics
•••
•••
•••
•••
•••
•••
•••
•••
Eli Lilly and Company
•••
•••
•••
•••
Revenue data requires full access. *2nd & 3rd tier companies available on enquiry.
According to Cognitive Market Research, the global Next Generation Diabetes Therapy and Drug Delivery market size was USD 10215.6 million in 2024. It will expand at a compound annual growth rate (CAGR) of 15.20% from 2024 to 2031.
North America held the major market share for more than 40% of the global revenue with a market size of USD 4086.24 million in 2024 and will grow at a compound annual growth rate (CAGR) of 13.4% from 2024 to 2031.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD 3064.68 million in 2024 and will grow at a compound annual growth rate (CAGR) of 13.7% from 2024 to 2031.
Asia Pacific held a market share of around 23% of the global revenue with a market size of USD 2349.59 million in 2024 and will grow at a compound annual growth rate (CAGR) of 17.2% from 2024 to 2031.
Latin America had a market share of more than 5% of the global revenue with a market size of USD 510.78 million in 2024 and will grow at a compound annual growth rate (CAGR) of 14.6% from 2024 to 2031.
Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD 204.31 million in 2024 and will grow at a compound annual growth rate (CAGR) of 14.9% from 2024 to 2031.
The CGM systems held the highest Next Generation Diabetes Therapy and Drug Delivery market revenue share in 2024.
Introduction of the Next Generation Diabetes Therapy and Drug Delivery Market
In order to enhance diabetes care, cutting-edge therapies, and creative delivery methods are included in the next-generation diabetes therapy and drug delivery market. Aiming to improve patient outcomes and lower complications, these include new insulin analogs, non-invasive glucose monitors, artificial pancreas devices, and smart insulin pens. The market is influenced by factors such as an increasing rate of diabetes, a requirement for less intrusive and more convenient treatment choices, and modifications in drug delivery technology. Challenges include, but are not limited to, exorbitant expenses, strict regulations, and competition from conventional medicines. The market's growth trajectory is also shaped by factors such as compliance among patients, the healthcare infrastructure, and the uptake of digital health technology.
November 2022: The plans for the U.S. introduction of Eli Lilly and Company's Tempo Personalized Diabetes Management Platform were announced. The new platform is intended to help doctors and adult patients manage type 1 or type 2 diabetes by providing data-driven, well-informed decisions. (Source:https://investor.lilly.com/news-releases/news-release-details/lilly-begin-rollout-tempor-personalized-diabetes-management)
Global Next Generation Diabetes Therapy and Drug Delivery Market Analysis Insights Video
Conclusion
The global Next Generation Diabetes Therapy and Drug Delivery market will expand significantly by 15.20% CAGR between 2024 and 2031.
CGM devices provide real-time glucose monitoring, which improves glycemic control, reduces the need for fingerstick tests, and optimizes insulin dosage for better diabetes control.
The market is dominated by the adult population, which drives demand for cutting-edge treatments like insulin pumps and CGM systems to control the increasing prevalence of type 2 diabetes.
Analyst Conclusion
Conclusion
The global Next Generation Diabetes Therapy and Drug Delivery market will expand significantly by 15.20% CAGR between 2024 and 2031.
CGM devices provide real-time glucose monitoring, which improves glycemic control, reduces the need for fingerstick tests, and optimizes insulin dosage for better diabetes control.
The market is dominated by the adult population, which drives demand for cutting-edge treatments like insulin pumps and CGM systems to control the increasing prevalence of type 2 diabetes.
Supriya Yadav
Research Analyst at Cognitive Market Research · Cognitive Market Research
As a Research Analyst, I bring over two years of experience in market research, data analysis, and market estimation. I specialize in turning complex datasets into meaningful insights that help businesses identify opportunities, understand market dynamics, and make confident, growth-focused decisions.
My expertise spans across analyzing industry trends, forecasting market potential, mapping competitive landscapes, and studying consumer behavior to deliver actionable recommendations. With an MBA in Marketing and Finance, I combine strong analytical skills with strategic thinking, ensuring that every project I work on contributes real value to clients.
I am passionate about using research to uncover patterns, anticipate shifts, and deliver insights that drive measurable business impact. My goal is to continuously learn, innovate, and provide data-driven solutions that empower clients to succeed in a competitive environment.
The global market size for Next Generation Diabetes Therapy and Drug Delivery in 2024 is USD 10215.6 million.
The global Next Generation Diabetes Therapy and Drug Delivery market is expected to grow with a CAGR of 15.20% over the projected period.
North America held a significant global Next Generation Diabetes Therapy and Drug Delivery market revenue share in 2024.
Asia-Pacific will witness the fastest growth of the global Next Generation Diabetes Therapy and Drug Delivery market over the coming years.
The US had the most significant global Next Generation Diabetes Therapy and Drug Delivery market revenue share in 2024.
The main drivers of the growth of the Next Generation Diabetes Therapy and Drug Delivery market are the demand for improved glycemic control, integration of digital health technologies, and government initiatives and funding.
The CGM systems segment had the largest share in the global Next Generation Diabetes Therapy and Drug Delivery market by product.
★ Reviews
No reviews yet — be the first!
Rate this report
Global Next Generation Diabetes Therapy and Drug Delivery Market Analysis — Table of Contents
Disclaimer: Redacted sample for representative purposes. Charts and data do not depict actual statistics. TOC varies by license selection.
18.6 Future Gross Margin Outlook and Profitability Trends
19.1 Key Takeaways
Here the analyst will summarize the content of entire report and will share his view point on the current industry scenario and how the market is expected to perform in the near future. The points shared by the analyst are based on his/her detailed in-depth understanding of the market during the course of this report study.
You will be provided exclusive rights to interact with the concerned analyst for unlimited time pre purchase as well as post purchase of the report.
19.2 Analyst Point of View
19.3 Assumptions and Acronyms
20.1 Primary Data Collection
20.1.1 Steps for Primary Data Collection
20.1.1.1 Identification of KOL
20.1.2 Backward Integration
20.1.3 Forward Integration
20.1.4 How Primary Research Help Us
20.1.5 Modes of Primary Research
20.2 Secondary Research
20.2.1 How Secondary Research Help Us
20.2.2 Sources of Secondary Research
20.3 Data Validation
20.3.1 Data Triangulation
20.3.2 Top Down & Bottom Up Approach
20.3.3 Cross check KOL Responses with Secondary Data
20.4 Data Representation
Sample Format of Deliverables
The Tables, Graphs/Charts are only for representative purposes and do not depict actual statistics. Purchase full Report access to actual data.
Cognitive Market Research employs "The Full Truth™" methodology — a rigorous triangulation process that combines primary research, secondary validation, and expert calibration. Implemented by Supriya Yadav and team for the Global Next Generation Diabetes Therapy and Drug Delivery Market Analysis Market analysis.
01
Primary Intelligence Gathering
Direct interviews with 50+ industry stakeholders including manufacturers, distributors, end-users, and regulatory bodies across all six regions.
02
Secondary Data Triangulation
Cross-referencing against trade databases, customs records, financial filings, patent databases, and verified industry publications.
03
Expert Validation Protocol
Each data point undergoes validation by minimum two independent domain experts with 15+ years of industry experience.
04
Athenaeum AI Processing
Our proprietary AI platform aggregates, normalizes, and identifies patterns across 10,000+ data points to surface non-obvious insights.
05
Editorial & QA Review
Final review by senior analysts ensures accuracy, coherence, and actionability of all insights and recommendations.
To maintain the integrity of our proprietary methodology and protect our elite expert network, specific source disclosures are reserved for full-access partners. Our research framework is anchored by a 70:30 primary-to-secondary ratio, ensuring your strategy is driven by real-time market intelligence rather than recycled, publicly available, or AI-generated data. Every deliverable includes an exhaustive source directory and grants direct analyst access.
Latest News about Next Generation Diabetes Therapy and Drug Delivery Market
Sources from Medical Devices & Consumables Industry
We don't just hand over data. We partner with your team across three integrated service lines — each designed to give you decision-grade intelligence on the Global Next Generation Diabetes Therapy and Drug Delivery Market Analysis market.
Service 01
Market Survey
B2BB2C
Structured primary research across both B2B and B2C channels. We design and execute custom surveys targeting manufacturers, distributors, procurement heads, and end-consumers in the global next generation diabetes therapy and drug delivery market analysis ecosystem — validated by our global panel of 10,000+ industrial respondents.
What's Included
Buyer intent & sentiment analysis
Purchase cycle mapping
Price sensitivity research
Channel preference profiling
Competitive perception study
Most Requested
Service 02
Customized Market Data & Reports
CustomReady Report
Choose from our ready-to-access 8th Edition report or commission a fully customized dataset tailored to your exact strategic questions. Cross-splits, custom geographies, proprietary segmentation — we build the intelligence asset your board actually needs.
What's Included
Ready syndicate report (250+ pages)
Custom data scope & segmentation
Excel quantitative models
Board-ready PPT with key findings
Secure cloud portal access
Service 03
Strategic Consultation
With SurveyWith Report
Every survey and every report comes with dedicated analyst consultation. Our senior research team walks your leadership through findings, answers strategic questions in real-time, and helps translate data into your next board presentation or investment thesis.
What's Included
Dedicated analyst assigned to you
Live walkthrough of findings
Strategic Q&A sessions
Go-to-market recommendations
NDA-protected engagement
Customize This Report
Tell us the specific segments, regions, or companies you need — and we will tailor the deliverable to your requirements.
